相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study)
Gyuri Kim et al.
DIABETES OBESITY & METABOLISM (2020)
Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
Kristian B. Filion et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
Oliver Schnell et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications
David S. H. Bell et al.
DIABETES OBESITY & METABOLISM (2019)
Clinical Use of DPP-4 Inhibitors
Baptist Gallwitz
FRONTIERS IN ENDOCRINOLOGY (2019)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
An empirical assessment of immeasurable time bias in the setting of nested case-control studies: Statins and all-cause mortality among patients with heart failure
In-Sun Oh et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study
Cintia Cercato et al.
DIABETOLOGY & METABOLIC SYNDROME (2019)
Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials
Dario Giugliano et al.
ENDOCRINE (2019)
Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies
A. J. Scheen
DIABETES & METABOLISM (2018)
Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
Antonios Douros et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
Antonios Douros et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data
Jee-Ae Kim et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2017)
Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients
Fei Wang et al.
MEDICINE (2017)
Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes A retrospective cohort study
Hyouk-Jun Chin et al.
MEDICINE (2017)
Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise
Juri Park et al.
DIABETES OBESITY & METABOLISM (2017)
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events
Antonios Douros et al.
DIABETES CARE (2017)
No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives
Mugdha Gokhale et al.
DIABETES OBESITY & METABOLISM (2017)
Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies
Laurent Azoulay et al.
DIABETES CARE (2017)
Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension
Sang-Mo Hong et al.
DIABETES OBESITY & METABOLISM (2017)
Cardiovascular Effects of Incretin-Based Therapies
William B. White et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register
Nils Ekstrom et al.
DIABETES OBESITY & METABOLISM (2016)
Sensitivity Analysis Without Assumptions
Peng Ding et al.
EPIDEMIOLOGY (2016)
Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials
J. Kongwatcharapong et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis
Gianluigi Savarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
A Multicenter Observational Study of Incretin-based Drugs and Heart Failure
Kristian B. Filion et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
Ling Li et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
Ling Li et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus
Shuo-Ming Ou et al.
ANNALS OF INTERNAL MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research
Benjamin M. Leon et al.
WORLD JOURNAL OF DIABETES (2015)
Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus - a retrospective nationwide study
U. M. Mogensen et al.
DIABETES OBESITY & METABOLISM (2014)
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Cardiovascular effects of gliptins
Andre J. Scheen
NATURE REVIEWS CARDIOLOGY (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Immortal time bias in pharmacoepidemiology
Samy Suissa
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes A Randomized Controlled Trial
Hisao Ogawa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
分享论文
